跳至主要内容
临床试验/NCT04281004
NCT04281004已完成1 期

A Phase I/II Randomized, Double-Masked Placebo-Controlled Study For Determining The Safety Of Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy

University of Utah2 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2020年7月10日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
61
试验地点
2
主要终点
Safety - Adverse Events Including Serious Adverse Events

研究概览

简要总结

This is a randomized, double-masked, placebo-controlled study to determine the safety of pAF in patients who undergo PRK.

详细描述

Photorefractive Keratectomy (PRK) is a common elective surgery used to correct refractive errors. We propose that amniotic fluid drops may be beneficial in promoting ocular surface healing following PRK. Purified amniotic fluid (pAF) contains anti-inflammatory, anti-microbial and regenerative factors similar to solid amniotic membrane. Individual patients will be randomized to one of two post-operative drop regimens, control eyes that will receive placebo saline solution (NaCl 0.9%, Baxter Medical), and study eyes that will receive pAF four times daily for seven days.

This is a randomized, double-masked, placebo-controlled study to determine

  • the safety of pAF in patients who undergo PRK
  • if pAF hastens re-epithelialization following PRK compared to placebo
  • if pAF reduces post-operative pain following PRK compared to placebo
  • if pAF affects visual outcome following PRK compared to placebo
  • if pAF affects ocular surface staining and corneal regularity following PRK compared to placebo

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Safety - Adverse Events Including Serious Adverse Events

时间窗: Up to 12 months after the last study dose

Ocular adverse events using MedDRA and CTCAE and serious adverse events

次要结局

  • Time to Complete Re-epithelization(Post-operative days 1 - 8)
  • Pain in Each Eye(Post-operative days 1 - 8)
  • Uncorrected Visual Acuity(Post-operative months 1, 3, 6, and 12)
  • Count of Participants Who Reported Oral Pain Medication Usage(Post-operative days 1 - 8)
  • Corneal Staining in Each Eye(Post-operative months 1, 3, 6, and 12)
  • Corneal Surface Regularity(Post-operative months 1, 3, 6, and 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark Mifflin

MD

University of Utah

研究点 (2)

Loading locations...

相似试验